|
|
NCOR2 |
nuclear receptor corepressor 2 |
- PPARA activates gene expression
- NOTCH1 Intracellular Domain Regulates Transcription
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- HDACs deacetylate histones
- Notch-HLH transcription pathway
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of transcription cofactors
- Regulation of lipid metabolism by PPARalpha
- Loss of MECP2 binding ability to the NCoR/SMRT complex
- Regulation of MECP2 expression and activity
- NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
- HCMV Early Events
- NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
- Cytoprotection by HMOX1
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
|
|
|
NFKBIA |
NFKB inhibitor alpha |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- SARS-CoV-1 activates/modulates innate immune responses
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- Acetylsalicylic acid
- Bardoxolone methyl
- Astaxanthin
|
- Hodgkin lymphoma
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
|
|
|
NR0B2 |
nuclear receptor subfamily 0 group B member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
|
NR2C1 |
nuclear receptor subfamily 2 group C member 1 |
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
|
|
|
|
|
NR2E3 |
nuclear receptor subfamily 2 group E member 3 |
|
|
- Retinitis pigmentosa (RP)
- Vitreoretinal degeneration, including: Stickler syndrome type I (STL1); Stickler syndrome type II (STL2); Snowflake vitreoretinal degeneration (SVD); Wagner syndrome 1 (WGN1); Knobloch syndrome (KNO); Enhanced S-cone syndrome (ESCS); Autosomal dominant vitreoretinochoroidopathy (ADVIRC)
|
|
|
NRIP1 |
nuclear receptor interacting protein 1 |
- SUMOylation of transcription cofactors
- Estrogen-dependent gene expression
- NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
- NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis
- Heme signaling
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
- 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE
|
|
|
|
PARP1 |
poly(ADP-ribose) polymerase 1 |
- POLB-Dependent Long Patch Base Excision Repair
- vRNA Synthesis
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SUMOylation of DNA damage response and repair proteins
- HDR through MMEJ (alt-NHEJ)
- DNA Damage Recognition in GG-NER
- Formation of Incision Complex in GG-NER
- Dual Incision in GG-NER
|
- Theophylline
- Zinc
- Carba-nicotinamide-adenine-dinucleotide
- NU1025
- Nicotinamide
- 2-{3-[4-(4-Fluorophenyl)-3,6-Dihydro-1(2h)-Pyridinyl]Propyl}-8-Methyl-4(3h)-Quinazolinone
- 3-Methoxybenzamide
- 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide
- 3,4-Dihydro-5-Methyl-Isoquinolinone
- 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide
- 6-AMINO-BENZO[DE]ISOQUINOLINE-1,3-DIONE
- Veliparib
- A-620223
- 5-FLUORO-1-[4-(4-PHENYL-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL]QUINAZOLINE-2,4(1H,3H)-DIONE
- Olaparib
- Talazoparib
- Niraparib
- Rucaparib
- Iniparib
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
PHB2 |
prohibitin 2 |
- Processing of SMDT1
- Cellular response to mitochondrial stress
|
- Capsaicin
- Rocaglamide
- Didesmethylrocaglamide
|
|
|
|
PIAS2 |
protein inhibitor of activated STAT 2 |
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
|
PML |
PML nuclear body scaffold |
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Regulation of TP53 Activity through Acetylation
- Interferon gamma signaling
- Regulation of RUNX1 Expression and Activity
- Regulation of PTEN localization
- HCMV Early Events
|
|
- Acute myeloid leukemia (AML)
|
|
|
PPARD |
peroxisome proliferator activated receptor delta |
- Carnitine shuttle
- Nuclear Receptor transcription pathway
- Signaling by Retinoic Acid
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Valproic acid
- Treprostinil
- Rosiglitazone
- Sulindac
- Bezafibrate
- Phthalic Acid
- Heptyl glucoside
- Oleic Acid
- cis-Vaccenic acid
- Elafibranor
- KD3010
- Cardarine
- (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid
- 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid
- Indeglitazar
- {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid
- Clinofibrate
- Glycerin
- Fenofibric acid
- Fish oil
|
|
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Thyroid cancer
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Type II diabetes mellitus
|
|
|
PPP4C |
protein phosphatase 4 catalytic subunit |
- Processing of DNA double-strand break ends
|
|
|
|
|
PPP4R1 |
protein phosphatase 4 regulatory subunit 1 |
|
|
|
|
|
PRKDC |
protein kinase, DNA-activated, catalytic subunit |
- Cytosolic sensors of pathogen-associated DNA
- IRF3-mediated induction of type I IFN
- Nonhomologous End-Joining (NHEJ)
- E3 ubiquitin ligases ubiquitinate target proteins
|
|
|
|
|
RARA |
retinoic acid receptor alpha |
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Signaling by Retinoic Acid
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Transcriptional regulation of granulopoiesis
- Transcriptional regulation of granulopoiesis
- TGFBR3 expression
|
- Adapalene
- Acitretin
- Alitretinoin
- Tretinoin
- Tazarotene
- Etretinate
- Isotretinoin
- Tamibarotene
- LGD-1550
- Trifarotene
|
- Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate
- Acute myeloid leukemia (AML)
|
|
|
RB1 |
RB transcriptional corepressor 1 |
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- Inhibition of replication initiation of damaged DNA by RB1/E2F1
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Condensation of Prophase Chromosomes
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Oncogene Induced Senescence
- Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
- Cyclin E associated events during G1/S transition
- Cyclin D associated events in G1
- Cyclin A:Cdk2-associated events at S phase entry
- RUNX2 regulates osteoblast differentiation
- Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
- Defective translocation of RB1 mutants to the nucleus
- Replication of the SARS-CoV-1 genome
- Aberrant regulation of mitotic exit in cancer due to RB1 defects
- Replication of the SARS-CoV-2 genome
- Nuclear events stimulated by ALK signaling in cancer
- Positive Regulation of CDH1 Gene Transcription
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
|
|
- Chronic myeloid leukemia (CML)
- Breast cancer
- Osteosarcoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Esophageal cancer
- Glioma
- Bladder cancer
|
|
|
RBBP4 |
RB binding protein 4, chromatin remodeling factor |
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by DREAM complex
- Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
- G0 and Early G1
- Polo-like kinase mediated events
- PRC2 methylates histones and DNA
- Oxidative Stress Induced Senescence
- HDACs deacetylate histones
- PKMTs methylate histone lysines
- ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Deposition of new CENPA-containing nucleosomes at the centromere
- Regulation of TP53 Activity through Acetylation
- Cyclin E associated events during G1/S transition
- G1/S-Specific Transcription
- Cyclin A:Cdk2-associated events at S phase entry
- RNA Polymerase I Transcription Initiation
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Transcriptional Regulation by E2F6
- HCMV Early Events
- Potential therapeutics for SARS
- Defective pyroptosis
- Negative Regulation of CDH1 Gene Transcription
- Regulation of endogenous retroelements by KRAB-ZFP proteins
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
- Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
- Regulation of PD-L1(CD274) transcription
|
|
|
|
|
RELA |
RELA proto-oncogene, NF-kB subunit |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NF-kB is activated and signals survival
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated NF-kB activation
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- PKMTs methylate histone lysines
- Transcriptional regulation of white adipocyte differentiation
- TAK1-dependent IKK and NF-kappa-B activation
- Interleukin-1 processing
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- CD209 (DC-SIGN) signaling
- CLEC7A/inflammasome pathway
- The NLRP3 inflammasome
- Transcriptional Regulation by VENTX
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- Purinergic signaling in leishmaniasis infection
- SARS-CoV-1 activates/modulates innate immune responses
- Regulation of NFE2L2 gene expression
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Regulation of PD-L1(CD274) transcription
|
- Glucosamine
- Dimethyl fumarate
- SC-236
|
|
|
|
RUNX1T1 |
RUNX1 partner transcriptional co-repressor 1 |
|
|
- Acute myeloid leukemia (AML)
|